CNTB - Connect Bio completes enrollment in mid-stage CBP-307 trial in ulcerative colitis

Connect Biopharma (NASDAQ:CNTB) has completed full enrollment of the Phase 2 clinical trial evaluating CBP-307 in adult patients with moderate-to-severe Ulcerative Colitis (UC). Shares down 36.4% premarket at $7.70. This global, phase 2 trial is being conducted at multiple sites, including U.S., to evaluate the efficacy and safety of CBP-307 in 134 subjects, where CBP-307 or placebo is expected to be administered to eligible adult subjects with moderate-to-severe UC for 12 weeks (induction phase). Following this 12-week induction phase, responders to treatment are expected to be treated for a further 36 weeks in a double-blind manner, with non-responders expected to enter an open-label arm and be treated for an additional 36 weeks (maintenance phase). “We look forward to announcing topline results of the 12-week induction phase of this trial by the end of the first quarter of 2022,” said Zheng Wei, PhD, Co-Founder and CEO of Connect Biopharma. Earlier, the company reported that its

For further details see:

Connect Bio completes enrollment in mid-stage CBP-307 trial in ulcerative colitis